(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Radiation therapy is associated with improved survival in surgically resected pT4 or N+ patients with ampullary adenocarcinoma.

Paul P. Koffer, MD, Kathryn Huber, MD, PhD; Tufts Medical Center

OBJECTIVE: The role of radiation therapy (RT) in the setting of surgically resected ampullary adenocarcinoma (AA) is not well defined. We examined the association of RT with survival in resected AA.

METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (8.2.1) was queried for patients with surgically resected AA diagnosed between 2004–2012 and aged = 20 years treated with or without RT. Patients were excluded if they had metastatic disease. Patients who were considered to be at high risk (defined as T4 or N+) were analyzed as a separate subgroup. Baseline characteristics were compared using the chi-squared test. Overall survival (OS) and cause-specific survival (CSS) were analyzed by Kaplan-Meier method and compared using log-rank test. Multivariable analysis with Cox regression was used to assess the association of survival and variables, including T stage, N stage, grade, age, and RT.

RESULTS: A total of 2,034 patients with surgically resected AA were identified. Overall, 25.1% of patients received RT. Patients who received RT were younger (P < .001) and had higher T stage (P < .001), N stage (P < .001), and tumor grade (P < .001). At 5 years, RT use was associated with a worse OS (35.1% vs 43.4%; P =.050) and CSS (41.1% vs 52.5%; P =.005) in the overall cohort on univariate analysis. In the multivariate analysis, RT was not found to be detrimental to OS (hazard ratio [HR], 0.891 [95% CI, 0.763–1.041]) or CSS (HR, 0.811 [95% CI, 0.744–1.044]).

A high-risk cohort of 1,129 patients was identified with T4 or N+ disease, of whom 35.8% received RT. At 5 years, RT was associated with improved OS (30.9% vs 24.2%; P =.001) and CSS (35.5% vs 30.9%; P =.016) on univariate analysis in this high-risk group. In the multivariate analysis, RT maintained its association with improved OS (HR, 0.784 [95% CI, 0.660–0.930]) and CSS (HR, 0.794 [95% CI, 0.661–0.954]) in this group.

CONCLUSION: RT is associated with improved survival in surgically resected pT4 or N+ patients with AA.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Related Content